Full Text View
Tabular View
No Study Results Posted
Related Studies
Caffeine for Excessive Daytime Somnolence in Parkinson's Disease
This study is currently recruiting participants.
Study NCT00459420   Information provided by McGill University Health Center
First Received: April 11, 2007   Last Updated: February 16, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Parkinson's Disease
Excessive Daytime Somnolence
Additional conditions recognized in this trial
Parkinson Disease
More general conditions related to this trial
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Parkinsonian Disorders
Interventions listed in this trial
Caffeine 100-200 mg BID
placebo
Additional drug interventions recognized in this trial
Caffeine
Caffeine citrate
More general drug interventions related to this trial
Central Nervous System Agents
Central Nervous System Stimulants
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Phosphodiesterase Inhibitors
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
McGill University Health Center
University of Toronto


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services